D-Mannose for Urinary Tract Infection

Verdict: Weak, mixed evidence; not proven for UTI prevention

D-Mannose is not a reliable way to prevent recurrent urinary tract infections: the largest, most rigorous trial found no benefit and pooled analyses are inconclusive. It appears safe, so some women may choose to try it, but it should never replace proven prevention or the antibiotics needed for an active infection.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is held down by a sharp split in trial quality. An early open-label RCT (Kranjcec 2014, PMID 23633128, n=308) reported a large protective effect rivaling the antibiotic nitrofurantoin, but its unblinded design carries a high risk of bias. The much larger, double-blind, placebo-controlled MERIT trial (PMID 38587819, n=598) was null: 51.0% of the D-Mannose group versus 55.7% on placebo still developed a UTI (p=0.26).

Two 2025 meta-analyses confirm the uncertainty rather than resolving it. Pooled risk ratios of 0.44 (PMID 41195062) and 0.57 (PMID 41004704) both crossed 1 and were not statistically significant, with very high between-trial heterogeneity (I-squared around 90%). In postmenopausal women the effect was essentially absent (RR 0.94). The 2022 Cochrane review (PMID 36041061) found little to no usable evidence and rated the certainty as very low.

Regulators and clinicians echo this caution. The UK NHS lists D-Mannose only as an optional self-care sugar you can buy as powder or tablets, not a medicine; the EU's EFSA rejected the sole D-Mannose UTI health claim for insufficient evidence; the US FDA issued a warning letter against UTI-prevention marketing; and the 2025 AUA/CUA/SUFU statement says monotherapy may not be effective. Because side effects are minor, mainly mild diarrhea, it earns a weak rather than a fully refuted grade.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.48
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
81%
Highly consistent evidence
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.485
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (0 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial (MERIT)
PMID: 38587819 2024 RCT (double-blind) n = 598
Finding: 51.0% in D-mannose group vs 55.7% in placebo experienced subsequent UTI; risk difference -5% (95% CI -13% to 3%, p=0.26). D-Mannose did NOT reduce recurrent UTI in primary care.
🟢 High quality Government Effect size: Risk difference -5%; 95% CI -13% to 3%; non-significant
View on PubMed
D-Mannose for prevention of recurrent urinary tract infection in adult women: An updated systematic review and meta-analysis of randomized controlled trials
PMID: 41195062 2025 統合分析 n = 890
Finding: Pooled RR 0.44 (95% CI 0.18-1.11, p=0.082) — non-significant. High heterogeneity I²=90%. Authors conclude prophylaxis with D-mannose did not produce a statistically significant difference in recurrent UTI risk.
Effect size: RR 0.44; 95% CI 0.18-1.11; NS
View on PubMed
Efficacy of D-mannose as prophylaxis of recurrent urinary tract infection: a systematic review and meta-analysis of randomized controlled trials
PMID: 41004704 2025 統合分析 n = 1,167
Finding: D-mannose vs control: RR 0.57 (95% CI 0.29-1.15); D-mannose vs antibiotics: RR 0.39 (95% CI 0.12-1.25). Neither comparison reached significance. In postmenopausal women specifically RR 0.94 (0.79-1.12).
Effect size: RR 0.57; 95% CI 0.29-1.15; NS
View on PubMed
D-mannose for preventing and treating urinary tract infections (Cochrane Review)
PMID: 36041061 2022 Cochrane SR n = 719
Finding: 「Little to no evidence to support or refute the use of D-mannose to prevent or treat UTIs in all populations.」 Certainty of evidence rated very low across comparisons due to methodological limitations and heterogeneity.
🟢 High quality Effect size: No pooled estimate — very low certainty
View on PubMed
D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial (Kranjcec et al.)
PMID: 23633128 2014 RCT (open-label) n = 308
Finding: UTI recurrence: D-mannose 14.6%, nitrofurantoin 20.4%, no-prophylaxis 60.8%. D-mannose significantly reduced UTI vs no prophylaxis (RR 0.24, p<0.001), comparable to nitrofurantoin. Side effects: D-mannose 8.2% vs nitrofurantoin 30.2%.
🟠 Limited quality Effect size: RR 0.24 (vs no prophylaxis); NS vs nitrofurantoin
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Advanced U-Tract consists of D-mannose, which is used to help prevent bacteria from adhering to the walls of the urinary tract and reduce the occurrence of urinary tract infections. ... Therefore, this product is intended for treatment of diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. As such, adequate directions cannot be writt… source↗
L4b EU EFSA
Against
L4c UK NHS
Cautious
D-mannose – a sugar you can buy as a powder or tablets to take every day source↗
L4d TW TFDA / 衛福部
Neutral
D-甘露糖屬自然界存在的單糖,為葡萄糖異構體,可以從植物與微生物中獲得,被廣泛應用於食品、化妝品以及醫藥業等領域。 source↗
L5c Cleveland Clinic
Neutral
L5d Harvard Health
Neutral
L5e Specialty Society (condition-mapped)
Neutral
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-uti-INT-d-mannose-001 繁體中文版 →